---
title: "Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295952472.md"
description: "Jasper Therapeutics reported a narrowed Q2 2026 net loss of $2.8M ($0.10 EPS), down 90% YoY, remaining pre-revenue. Key developments include the July 2026 acquisition of Kira, a $132M preferred-stock financing, and an out-license of KP-301/KP-402 to Mirador. The company discontinued non-core programs to focus on immunology biologics, advancing KP-104 toward Phase 2/3 readiness and planning briquilimab BLA for Q1 2027."
datetime: "2026-08-14T15:11:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295952472.md)
  - [en](https://longbridge.com/en/news/295952472.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295952472.md)
generator: "portal-rs"
---

# Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q Summary

Jasper Therapeutics, Inc. reported a narrowed net loss in the second quarter of 2026, posting a net loss attributable to common stockholders of $(2.8M), or $(0.10) per share diluted, versus a $(26.7M) loss, or $(1.74) per share, in the year‑ago quarter. The company remains pre‑revenue with no product sales reported for the period.

**Financial Highlights**

-   Net income: Net loss attributable to common stockholders of $(2.8M) for 2Q 2026, compared with a net loss of $(26.7M) in 2Q 2025 (‑90% YoY reduction in loss).
-   Diluted EPS: Net loss per share, basic and diluted, of $(0.10) for 2Q 2026 versus $(1.74) in the year‑ago quarter.
-   Revenue: No product revenue reported; company remains pre‑revenue in this filing.

**Business Highlights**

-   Merger & strategic repositioning: Completed the acquisition of Kira in July 2026, consolidating the pipeline and refocusing the company on immunology biologics.
-   Pipeline milestones: Advancing KP‑104 toward Phase 2/3 readiness with interim data expected in Q4 2026 and end‑of‑Phase 2 planning in H1 2027; pre‑BLA planning for briquilimab targeted for Q1 2027.
-   Portfolio optimization: Discontinued non‑core programs (asthma, SCID, MDS/AML) following a 2025 reorganization to prioritize higher‑value assets and reduce cash burn.
-   Capital and operations: Completed $132M preferred‑stock financing in July 2026 to fund clinical programs and announced an out‑license of KP‑301/KP‑402 to Mirador to concentrate resources on priority programs.

Original SEC Filing: Jasper Therapeutics, Inc. \[ JSPR \] - 10-Q - Aug. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [JSPR.US](https://longbridge.com/en/quote/JSPR.US.md)

## Related News & Research

- [Jasper Therapeutics to join H.C. Wainwright Global Investment Conference fireside chat](https://longbridge.com/en/news/298454216.md)
- [Braze, Inc. 2026: Revenue $227.23M, EPS ($0.17) — 10-Q Summary](https://longbridge.com/en/news/298436148.md)
- [Essex Property Trust declares Q3 2026 dividend of R$ 0.89 per unit](https://longbridge.com/en/news/298322539.md)
- [Annaly Capital declares Q3 2026 dividend of $0.75 per share](https://longbridge.com/en/news/298499808.md)
- [Acteos delays H1 2026 results release to Oct. 28](https://longbridge.com/en/news/298618428.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**